SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has expanded the clinical footprint of its SSi Mantra surgical robotic system with the launch of a robotic cardiac surgery program at HCG Hospital, Mithakhali, in Ahmedabad, India. The program commenced with a robotic left internal mammary artery (LIMA) take-down performed using the SSi Mantra 3.0 system. The procedure was led by Dr. Brajmohan Singh and proctored by Dr. Lalit Malik, with support from the SS Innovations team. This achievement underscores the growing adoption of robotic-assisted cardiac surgery in the region and highlights the potential of the SSi Mantra system to enhance surgical precision and patient outcomes.
The SSi Mantra system has seen significant global traction, with 238 systems installed as of September 8, 2026, representing a 42% increase from the end of 2025. The system is now installed across 12 countries, with recent expansion into Colombia, Sri Lanka, and the Philippines. This growth reflects the company's strategic efforts to penetrate international markets and establish its technology as a viable option for advanced surgical procedures. SS Innovations is also pursuing U.S. Food and Drug Administration (FDA) review and European Union CE marking, which, if successful, would allow the company to enter additional major markets and compete more directly with established robotic surgery platforms.
In a LinkedIn post, the company congratulated Dr. Brajmohan Singh, Dr. Lalit Malik, and the entire team at HCG Hospital for their achievement, thanking them for their trust and commitment to advancing robotic cardiac surgery in the region. The post also reiterated SS Innovations' commitment to enabling hospitals and surgeons with cutting-edge robotic technology. For more details on the company's initiatives, visit their SS Innovations International (NASDAQ: SSII) client page. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.
The launch of this program at HCG Hospital is important for several reasons. First, it demonstrates the increasing acceptance of robotic systems in cardiac surgery, a field that demands high precision and has traditionally been dominated by a few major players. The SSi Mantra's ability to perform complex procedures like LIMA take-down suggests it is a competitive alternative, which could lead to more affordable and accessible robotic surgery options in emerging markets. Second, the expansion into new countries indicates that SS Innovations is successfully executing its global strategy, which could drive revenue growth and strengthen its position in the medical device industry. Finally, the pursuit of FDA and CE marking signals the company's ambition to enter highly regulated markets, which could further accelerate adoption and validate its technology on a global scale. As robotic surgery continues to evolve, SS Innovations' progress will be closely watched by investors and healthcare providers alike. For a deeper dive into this announcement, Read More. Additionally, the original release can be viewed on www.newmediawire.com. Investors should note the forward-looking statements and risks detailed in the company's SEC filings, and can review the full terms of use and disclaimers at https://IBN.ai/Disclaimer.
